[
  {
    "question": "Young with left hemiparesis & confusion scenario consistent with MELAS pic multiple FLAIR DWI hyperintensity not following vascular territory, on admission worsen what to order next",
    "option_a": "Lactate pyruvate level",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) is a mitochondrial disorder characterized by stroke-like episodes that do not conform to traditional vascular territories, along with systemic features such as muscle weakness, seizures, and lactic acidosis. MELAS is most commonly caused by mutations in mitochondrial DNA (often the MT-TL1 gene) that impair oxidative phosphorylation. This leads to deficient energy production and an accumulation of lactate, which is responsible for many of its clinical manifestations. The stroke-like lesions seen on MRI are due to metabolic derangements rather than embolic or thrombotic events. A young patient presenting with left hemiparesis and confusion, along with MRI findings of hyperintensities on FLAIR/DWI that do not align with vascular territories, strongly suggests a stroke-like episode due to MELAS. The accumulation of lactate manifests as systemic lactic acidosis, making metabolic testing crucial. After clinical and radiologic suspicion, the next step is to order metabolic studies including serum and/or CSF lactate and pyruvate levels. Differential diagnoses include ischemic stroke, encephalitis, and other mitochondrial disorders. Muscle biopsy and genetic testing may be pursued later for definitive diagnosis. Management is largely supportive. First-line therapies include metabolic support with agents such as L-arginine, antioxidants, and vitamins. In pregnancy and lactation, medications are chosen with care to minimize fetal exposure while still managing mitochondrial dysfunction. Long-term surveillance and symptomatic management are essential as there is no cure. Option A, which calls for ordering lactate pyruvate level testing, is correct because it directly addresses the metabolic derangement typical of MELAS. Other options (if provided) might involve further imaging or invasive testing, but the metabolic panel is the most appropriate immediate step. 1. Stroke-like episodes in MELAS do not follow vascular distributions. 2. Elevated lactate levels are a hallmark of mitochondrial dysfunction. 3. Early diagnosis can prevent unnecessary invasive procedures. Recent research emphasizes the importance of early metabolic evaluation (including lactate and pyruvate levels) in suspected MELAS cases. Advances in mitochondrial medicine are focusing on targeted supportive therapies to improve quality of life.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario about Xeroderma pigmentosum clear (skin lesion and keratitis after sun exposure)",
    "option_a": "nalysis emphasizes an approach that focuses on UV protection, genetic confirmation, and multidisciplinary surveillance. The marked answer B aligns with these management strategies, making it the correct approach.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "Xeroderma Pigmentosum (XP) is a genetic disorder characterized by defective nucleotide excision repair, making the skin extremely sensitive to UV radiation. This sensitivity leads to early onset of skin lesions and ocular complications like keratitis. XP results from mutations in genes responsible for repairing ultraviolet-induced DNA damage. The inability to repair this damage causes cumulative mutations that lead to skin cancer and other UV-related damage, including keratitis due to corneal damage. Patients with XP typically present early in life with severe sun-sensitive skin changes such as freckling, pigmentary abnormalities, and a predisposition to cutaneous malignancies. Ocular involvement such as keratitis further supports the diagnosis. The diagnosis of XP is primarily clinical, supported by genetic testing if necessary. Differential diagnoses include conditions like porphyria cutanea tarda (which presents later and with different systemic features) and lupus erythematosus (which involves different immunologic profiles). Management centers on rigorous UV protection, including the use of high-SPF sunscreens, protective clothing, and UV-blocking eyewear. Regular dermatologic surveillance is required to promptly identify malignancies. During pregnancy and lactation, strict photoprotection and monitoring remain imperative since hormonal changes can influence skin sensitivity. Although specific answer choices were not given, the option analysis emphasizes an approach that focuses on UV protection, genetic confirmation, and multidisciplinary surveillance. The marked answer B aligns with these management strategies, making it the correct approach. 1. Early and strict UV protection is essential to limit cutaneous damage in XP. 2. Regular skin examinations can help in the early detection of malignancies. 3. Ocular protection is as important as skin protection due to the risk of keratitis. Current guidelines advocate for preventive management in XP, stressing UV avoidance and early dermatologic intervention. Emerging research is exploring gene therapy, but prevention remains the cornerstone of treatment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Criteria of TS",
    "option_a": "(Cardiac rhabdomyoma) is a recognized major diagnostic criterion for TSC. Option B (Renal angiomyolipoma) is equally a major criterion. Selecting only option A (as in the marked answer) is incomplete. The correct response should include both A and B, whereas options like optic glioma or neurofibroma would be incorrect because they are not part of the TSC criteria.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A, B",
    "subspecialty": "Neurogenetics",
    "explanation": "Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder characterized by the development of benign hamartomas in various organs, including the brain, heart, kidneys, and skin. Mutations in the TSC1 or TSC2 genes result in dysregulation of the mTOR signaling pathway, leading to uncontrolled cellular proliferation and hamartoma formation. Major features include cardiac rhabdomyomas and renal angiomyolipomas, both of which serve as diagnostic criteria. Cardiac rhabdomyomas are often detected in infancy and can be an early clue to TSC. Renal angiomyolipomas, frequently found in older children and adults with TSC, can lead to complications such as hemorrhage. The presence of these lesions correlates with the multisystem involvement typical of TSC. Diagnosis is based on a combination of clinical findings and imaging studies. Differential diagnoses include other neurocutaneous syndromes such as Neurofibromatosis type 1 (which may present with caf\u00e9-au-lait spots and optic gliomas) and Sturge-Weber syndrome. The presence of both cardiac and renal lesions strongly supports TSC. First-line management involves regular surveillance for neurological complications (e.g., seizures) and organ-specific tumors using imaging. mTOR inhibitors like everolimus are considered when tumors are symptomatic or cause complications. In pregnancy and lactation, careful monitoring is required to balance maternal benefits against potential fetal risks, and many interventions may be deferred until postpartum if possible. Option A (Cardiac rhabdomyoma) is a recognized major diagnostic criterion for TSC. Option B (Renal angiomyolipoma) is equally a major criterion. Selecting only option A (as in the marked answer) is incomplete. The correct response should include both A and B, whereas options like optic glioma or neurofibroma would be incorrect because they are not part of the TSC criteria. 1. Cardiac rhabdomyomas are often the earliest indicator of TSC in infancy. 2. Renal angiomyolipomas may cause significant morbidity if not monitored. 3. TSC diagnosis relies on a combination of dermatologic, neurologic, and radiologic findings. Recent consensus guidelines on TSC emphasize the importance of comprehensive, multidisciplinary evaluation and genetic testing. The use of mTOR inhibitors has shown promising results in reducing tumor burden, although cautious use is advised during pregnancy.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario suggestive of wilson, with KF ring, and MRI features what is next step to confirm dx",
    "option_a": "",
    "option_b": "",
    "option_c": "(Serum ceruloplasmin measurement) is the correct next step in confirming Wilson disease because it is a sensitive and readily available test. Option A (Liver biopsy), although a gold standard for quantifying hepatic copper, is invasive and reserved for ambiguous cases. Option B (Genetic testing) is supportive but complicated by allelic variability. The marked answer D is incorrect based on current diagnostic algorithms.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neurogenetics",
    "explanation": "Wilson disease is an autosomal recessive disorder of copper metabolism that results in toxic accumulation of copper in the liver, brain, and other tissues. Key features include hepatic dysfunction and neurological manifestations. Mutations in the ATP7B gene lead to impaired biliary copper excretion and diminished incorporation of copper into ceruloplasmin, causing copper accumulation. This results in hepatic damage and neurotoxicity. Kayser-Fleischer rings occur due to copper deposition in the Descemet\u2019s membrane of the cornea. Patients often present with a combination of liver dysfunction (ranging from asymptomatic elevations to fulminant hepatitis) and neurological symptoms (tremors, dystonia, psychiatric disturbances). The presence of KF rings supports the diagnosis in the appropriate clinical context. Once Wilson disease is suspected (especially with KF rings and suggestive MRI findings), serum ceruloplasmin measurement is the most appropriate and noninvasive next step. Differential diagnoses include other causes of liver or movement disorders, but the combination of hepatic, neurological, and ocular signs is highly suggestive of Wilson disease. First-line treatment consists of copper chelation therapy (e.g., penicillamine or trientine) and adjunctive zinc therapy to reduce copper absorption. In pregnant and lactating women, zinc therapy is often preferred due to its safer profile, but chelators may be used if necessary under careful supervision. Liver transplantation is considered in cases of fulminant liver failure. Option C (Serum ceruloplasmin measurement) is the correct next step in confirming Wilson disease because it is a sensitive and readily available test. Option A (Liver biopsy), although a gold standard for quantifying hepatic copper, is invasive and reserved for ambiguous cases. Option B (Genetic testing) is supportive but complicated by allelic variability. The marked answer D is incorrect based on current diagnostic algorithms. 1. Low serum ceruloplasmin (<20 mg/dL) is typically seen in Wilson disease. 2. Kayser-Fleischer rings are a key diagnostic clue, though their absence does not exclude the disease, especially in hepatic presentations. 3. Early diagnosis and treatment are critical to prevent irreversible neurological damage. Recent guidelines reinforce serum ceruloplasmin as the preferred initial diagnostic test in suspected Wilson disease. Advances in genetic testing are emerging, but current practice emphasizes noninvasive biochemical assessments before considering invasive procedures.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario suggestive of oculomotor apraxia what is the gene",
    "option_a": "is correct because the APTX gene is directly implicated in AOA1. Other potential options such as SETX (associated with AOA2) and ATM (associated with Ataxia Telangiectasia) are not linked with the classic presentation of isolated oculomotor apraxia with ataxia seen in AOA1.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Oculomotor apraxia refers to a disorder where patients have difficulty initiating purposeful saccadic eye movements. In Ataxia with Oculomotor Apraxia type 1 (AOA1), patients typically exhibit early-onset cerebellar ataxia along with oculomotor apraxia. The core concept here is the genetic mutation in the APTX gene leading to the clinical syndrome. The APTX gene encodes the protein aprataxin, which plays a key role in the repair of single-strand DNA breaks. Mutations in this gene lead to impaired DNA repair mechanisms, resulting in progressive neuronal degeneration, especially in the cerebellum and brainstem. This disrupted DNA repair process is now well-recognized as a contributing mechanism in AOA1. Patients with AOA1 typically present in childhood or adolescence with symptoms of gait ataxia, dysarthria, and difficulty initiating eye movements. The presence of oculomotor apraxia differentiates AOA1 from other ataxias, and sometimes mild peripheral neuropathy and elevated serum cholesterol may be noted. The absence of features such as telangiectasia (seen in Ataxia Telangiectasia) further assists in clinical differentiation. The diagnosis is confirmed with genetic testing that identifies mutations in the APTX gene. Differential diagnoses include AOA2 (caused by mutations in SETX, with a slightly different clinical and biochemical profile) and Ataxia Telangiectasia (linked to ATM gene mutations and characterized by immunodeficiency and telangiectasia). Neuroimaging and nerve conduction studies may aid in excluding other cerebellar and neuromuscular disorders. Currently, management of AOA1 is supportive, including physiotherapy, occupational and speech therapy. There is no disease-modifying treatment available. Regular follow-up, genetic counseling, and supportive interventions are recommended. In the context of pregnancy and lactation, genetic counseling is essential to assess recurrence risks and discuss management strategies, as there is no contraindication to supportive therapies during these periods. Option A is correct because the APTX gene is directly implicated in AOA1. Other potential options such as SETX (associated with AOA2) and ATM (associated with Ataxia Telangiectasia) are not linked with the classic presentation of isolated oculomotor apraxia with ataxia seen in AOA1. 1. APTX mutations leading to AOA1 often present in childhood with a combination of ataxia and oculomotor apraxia. 2. Elevated cholesterol is a supportive, though not universal, finding. 3. Differential diagnosis is essential to exclude other genetic ataxias such as AOA2 and Ataxia Telangiectasia. Recent studies emphasize the role of DNA repair dysfunction in AOA1 and explore potential avenues for targeted therapies. However, no effective disease-modifying treatments are currently available. Expert consensus guidelines continue to recommend comprehensive supportive care and genetic counseling.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "SEGA with which disease.",
    "option_a": "Something not related",
    "option_b": "Tuberous Sclerosis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "Subependymal giant cell astrocytoma (SEGA) is a benign brain tumor often seen in the context of tuberous sclerosis complex (TSC). TSC is a genetic disorder characterized by the development of hamartomas in multiple organs, including the brain, skin, kidneys, and heart. Tuberous sclerosis results from mutations in either the TSC1 or TSC2 genes. These genes normally regulate the mTOR (mammalian target of rapamycin) pathway, which controls cell growth and proliferation. Loss of function mutations lead to mTOR pathway hyperactivation and subsequent formation of benign tumors, including SEGAs, often localized in the subependymal region near the foramen of Monro. SEGAs can become clinically significant when they cause obstructive hydrocephalus by blocking cerebrospinal fluid flow, leading to symptoms such as headaches, nausea, and signs of increased intracranial pressure. Tuberous sclerosis is also associated with a range of cutaneous manifestations (e.g., ash-leaf spots, facial angiofibromas, shagreen patches) and systemic involvement. Diagnosis of TSC is based on clinical criteria combined with imaging findings. Brain MRI can detect SEGAs, while skin examination and other systemic evaluations support the diagnosis. The differential diagnosis includes other intracranial tumors such as central neurocytomas, but the systemic manifestations in TSC differentiate these conditions. Management involves both monitoring and active intervention. First-line treatment for symptomatic SEGAs includes the use of mTOR inhibitors like everolimus, which have been shown to reduce tumor size. Surgical resection is reserved for cases not responsive to medical therapy or when acute hydrocephalus ensues. During pregnancy and lactation, the use of mTOR inhibitors requires careful risk-benefit analysis, and surgical intervention might be preferred if the tumor poses significant risk. Multidisciplinary management including neurology, neurosurgery, and maternal-fetal medicine is essential. Option B is correct as tuberous sclerosis is the disease most commonly associated with SEGA. Other options that do not relate to tuberous sclerosis would not be consistent with the typical clinical and genetic profile of SEGA. 1. SEGAs are a hallmark of tuberous sclerosis and can lead to hydrocephalus if they grow large enough to block CSF pathways. 2. The use of mTOR inhibitors has revolutionized the management of SEGAs. 3. Multidisciplinary care is key in managing both TSC and its complications. Recent guidelines from the Tuberous Sclerosis Alliance and related neurology societies have reinforced the role of everolimus for reducing SEGAs and highlighted the need for regular surveillance imaging. Ongoing research is focused on optimizing dosing strategies and improving long-term outcomes, including considerations for pregnancy and lactation.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of cmt2 what you will find:",
    "option_a": "Decrease amplitude of sensory",
    "option_b": "Other choices going with demyelinating not axonal",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Charcot-Marie-Tooth disease (CMT) is a group of inherited peripheral neuropathies. CMT type 2 represents the axonal form of the disease, where the primary pathology involves axonal degeneration rather than demyelination. In CMT2, mutations in various genes (for example, MFN2 among others) lead to axonal degeneration. This results in reduced nerve fiber amplitude on nerve conduction studies, while conduction velocities typically remain within normal limits or are only mildly reduced because the myelin sheath is not primarily affected. Patients with CMT2 present with a slowly progressive distal muscle weakness, atrophy, and sensory loss. Foot deformities and gait abnormalities are common. The reduced amplitude of sensory responses on nerve conduction studies reflects the underlying axonal loss. Diagnosis is primarily made based on clinical examination and nerve conduction studies, which demonstrate decreased compound muscle and sensory action potential amplitudes. Genetic testing can further classify the subtype. Differential diagnoses include demyelinating neuropathies such as CMT1, where nerve conduction velocities are significantly slowed, as well as acquired neuropathies. Management of CMT2 is largely supportive, focusing on physical therapy, orthotic supports, and symptomatic management of pain and cramping. Genetic counseling is recommended, especially for family planning. During pregnancy and lactation, supportive measures and careful monitoring are emphasized as there are no specific contraindications to these therapies. Option A is correct as the decrease in the amplitude of sensory nerve action potentials is a hallmark finding in the axonal form of CMT (CMT2). Option B, which would be indicative of demyelination (e.g., markedly slowed conduction velocities), is more typical of CMT1 and is therefore incorrect in this scenario. 1. In CMT2, nerve conduction studies show decreased amplitudes with relatively preserved conduction velocities. 2. Axonal degeneration is the primary mechanism in CMT2, distinguishing it from the demyelinating CMT1. 3. Genetic testing is crucial for accurate subtyping and family counseling. Advancements in genetic sequencing have improved the diagnostic accuracy for CMT subtypes. Current research is exploring potential gene therapies and targeted treatments, although management remains supportive. New guidelines continue to emphasize the importance of multidisciplinary care and genetic counseling.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Paramyotonia congenita scenario: what is the channel (key is worsened by cold while patient eating ice cream! and induced/worsened by exercise)?",
    "option_a": "SCN4A",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Paramyotonia congenita is a type of non-dystrophic myotonia characterized by muscle stiffness that worsens with cold exposure and exercise. It is primarily a channelopathy involving skeletal muscle sodium channels. The condition is most commonly associated with mutations in the SCN4A gene, which encodes the alpha subunit of the voltage-gated sodium channel in skeletal muscle. These mutations alter channel function, leading to abnormal muscle excitability. Cold temperatures exacerbate the dysfunction, causing prolonged muscle membrane depolarization. Clinically, patients experience muscle stiffness and myotonia that worsens with exposure to cold (for instance, during the consumption of ice cream) and with repeated muscle activity. Symptoms are typically episodic and can be provoked by exercise. This clinical behavior helps differentiate it from other myotonias and channelopathies. Diagnosis is based on clinical history, examination, and electromyography (EMG) showing myotonic discharges. Genetic testing confirming mutations in SCN4A supports the diagnosis. Differential diagnoses include other sodium channelopathies and chloride channel myotonias (e.g., myotonia congenita caused by CLCN1 mutations), which have different triggers and clinical courses. Management is generally symptomatic. First-line treatment includes the use of sodium channel blockers such as mexiletine, which can reduce myotonia. Avoidance of cold and strenuous activity is advised. During pregnancy and lactation, careful medication selection is crucial; mexiletine\u2019s use should be evaluated on a risk-benefit basis with consultation from neuromuscular and obstetric specialists, and non-pharmacological measures (like avoiding cold exposure) remain first-line. Option A is correct as SCN4A is the gene most frequently implicated in paramyotonia congenita. The clinical scenario (worsening with cold and exercise) directly corresponds to the physiology of sodium channel dysfunction due to SCN4A mutations. Other channel genes would not account for this specific phenotype. 1. Paramyotonia congenita is a classic sodium channelopathy that worsens with cold and repetitive activity. 2. Genetic testing for SCN4A mutations is key to confirming the diagnosis. 3. Avoidance of cold exposure is a simple yet effective measure in managing symptoms. Recent studies have focused on the molecular mechanisms underlying sodium channel dysfunction in paramyotonia congenita. Updated guidelines emphasize a careful approach to therapeutic interventions, particularly in pregnant or lactating patients, to balance efficacy with safety. The role of mexiletine has been further validated in clinical trials, although individualized treatment remains essential.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Mode of inheritance for of adult familial ALS:",
    "option_a": "AD",
    "option_b": "AR",
    "option_c": "Juvenile > AR",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects both upper and lower motor neurons. Approximately 5-10% of ALS cases are familial, and in adult familial ALS the most common mode of inheritance is autosomal dominant. In familial ALS, mutations in genes such as C9orf72, SOD1, TDP-43 (TARDBP), and FUS lead to misfolded proteins, mitochondrial dysfunction, and impaired axonal transport. These genetic aberrations cause toxic protein aggregations triggering motor neuron degeneration. Clinically, patients present with a mixture of upper motor neuron signs (spasticity, hyperreflexia) and lower motor neuron signs (muscle weakness, atrophy). The progressive nature of motor impairment correlates with the underlying neurodegeneration. Diagnosis is based primarily on clinical findings combined with electromyography (EMG) studies and exclusion of mimic conditions. Differential diagnoses include primary lateral sclerosis, multifocal motor neuropathy, and spinal muscular atrophies, which can be differentiated based on specific neurological exam findings and electrophysiologic studies. Management is supportive and may involve medications such as riluzole (first-line) to modestly prolong survival and edaravone in some cases. Multidisciplinary care is essential including physical therapy, respiratory management, and nutritional support. For pregnant or lactating patients, the risks and benefits of riluzole must be carefully weighed, and consultation with neurology and obstetrics specialists is recommended. Option A (AD) is correct. Option B (AR) is incorrect for adult familial ALS. Option C, which suggests a juvenile autosomal recessive pattern, does not apply to the typical adult form. 1. Most adult familial ALS cases are autosomal dominant with common gene mutations such as C9orf72 and SOD1. 2. Diagnosis relies heavily on clinical presentation and electrophysiological testing. 3. Management remains supportive with modest success in slowing progression. Recent studies are exploring gene-targeted therapies and potential disease-modifying treatments. Current guidelines emphasize early multidisciplinary intervention, and research continues into understanding genetic variations and environmental interactions in ALS.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "? scenario of HSAN 1 (painful ulcer and mutilation) what is the gene:",
    "option_a": "SPTCL1",
    "option_b": "IKABh",
    "option_c": "TRKA",
    "option_d": "RAB7",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Hereditary Sensory and Autonomic Neuropathy type I (HSAN1) is a genetic disorder characterized by the degeneration of sensory and autonomic nerves, leading to loss of pain sensation, painful ulcerations, and eventual mutilation of extremities. HSAN1 is most commonly associated with mutations in the SPTLC1 gene (note: previously sometimes noted as SPTCL1), which encodes a subunit of the enzyme serine palmitoyltransferase. The mutation disrupts normal sphingolipid metabolism resulting in the accumulation of toxic deoxysphingolipids, leading to nerve degeneration. Clinically, patients present with distal sensory loss, neuropathic pain, and repetitive injuries due to the inability to detect pain. This sensory deficit can lead to the formation of chronic non-healing ulcers and subsequent mutilation, particularly of the feet and hands. Diagnosis is established through clinical history, neurological examination, nerve conduction studies, and confirmatory genetic testing of the SPTLC1 gene. Differential diagnoses include other HSAN subtypes (such as HSAN type IV, which involves the NTRK1 gene and leads to congenital insensitivity to pain with anhidrosis) and conditions such as diabetic neuropathy. Management is primarily supportive, focusing on pain management, strict wound care, and prevention of secondary infections. Genetic counseling is recommended. There is no curative treatment available. In pregnancy or lactation, management remains symptomatic with careful consideration of medications, and consultation with specialists is advised to avoid drugs that might affect fetal or neonatal outcomes. Option A (SPTCL1/SPTLC1 gene) is correct as it is the gene most commonly implicated in HSAN1. Option B (IKABh) is not associated with HSAN1. Option C (TRKA) is related to congenital insensitivity to pain with anhidrosis (HSAN type IV) rather than HSAN1. Option D (RAB7) is linked to other neuropathies such as Charcot-Marie-Tooth type 2B. 1. HSAN1 is most commonly due to mutations in the SPTLC1 gene affecting sphingolipid metabolism. 2. Patients present with painful sensory neuropathy and resultant ulcers that may lead to mutilation. 3. Genetic testing is vital for accurate diagnosis and genetic counseling. Recent research is focusing on the role of deoxysphingolipids in neuronal toxicity and exploring potential disease-modifying strategies targeting sphingolipid metabolism, though current treatment remains supportive.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of Wilson rx:",
    "option_a": "D-penicillamine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Wilson's disease is an autosomal recessive disorder of copper metabolism resulting from mutations in the ATP7B gene. It leads to copper accumulation, primarily affecting the liver and the brain. Defective copper excretion by the liver causes a toxic buildup of copper in hepatocytes and extrahepatic tissues (e.g., brain, cornea). This accumulation causes cellular injury via oxidative stress and inflammation, leading to hepatic dysfunction and neuropsychiatric symptoms. Clinically, Wilson's disease may present with hepatic signs (hepatitis, cirrhosis) and neuropsychiatric manifestations (movement disorders, tremors, dysarthria). Kayser-Fleischer rings, visible with slit-lamp examination, are a characteristic ocular finding. Initial diagnosis is based on clinical presentation, serum ceruloplasmin levels (usually low), 24-hour urinary copper excretion (elevated), and ophthalmologic examination for Kayser-Fleischer rings. The diagnosis is later confirmed by additional tests such as liver biopsy for copper quantification and sometimes genetic testing. The mainstay of treatment is copper chelation therapy. D-Penicillamine is a first-line chelator that binds copper allowing its excretion; however, due to its potential side effects, alternatives like trientine may be considered if intolerance occurs. In addition, zinc is used as maintenance therapy since it blocks copper absorption. During pregnancy or lactation, careful consideration is needed because D-penicillamine is associated with teratogenic risks; alternatives such as trientine or zinc may be favored, and close consultation with specialists is mandatory. Option A (D-Penicillamine) is correct as it has been the mainstay of treatment for Wilson's disease. Although newer agents may be used in certain scenarios, D-penicillamine remains a valid first-line therapy in many settings. The other options were not provided, thus solidifying Option A as the only appropriate choice in this scenario. 1. Early diagnosis and initiation of copper chelation can prevent irreversible organ damage in Wilson's disease. 2. D-Penicillamine is effective but requires monitoring for adverse reactions such as hypersensitivity and nephrotoxicity. 3. In pregnancy, alternative therapies with a better safety profile should be considered. Recent comparative studies are evaluating the efficacy and tolerability of trientine versus D-Penicillamine. Guidelines continue to support the use of D-Penicillamine as a first-line agent in many cases, though individualized patient factors, including potential pregnancy, may necessitate alternative approaches.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about Wilson what will confirm diagnosis:",
    "option_a": "Liver biopsy",
    "option_b": "Genetic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "The diagnosis of Wilson's disease involves establishing the presence of copper accumulation due to impaired copper metabolism. Confirmatory diagnostic tests are necessary to validate the clinical suspicion raised by liver, neurological, and ophthalmological findings. Mutations in the ATP7B gene impede the liver's ability to excrete copper into bile, leading to progressive deposition of copper in hepatic and extrahepatic tissues. This results in toxic copper accumulation, particularly in the liver and brain. Patients may present with hepatic dysfunction (ranging from asymptomatic liver enzyme abnormalities to fulminant hepatic failure), neuropsychiatric symptoms, and the ophthalmologic sign of Kayser-Fleischer rings. The severity of symptoms correlates with the level of hepatic copper deposition. While initial screening tests include serum ceruloplasmin measurement, 24-hour urinary copper, and slit-lamp examination for Kayser-Fleischer rings, a liver biopsy with quantitative copper measurement remains the gold standard for confirming the diagnosis. Differential diagnoses include other causes of liver disease such as autoimmune hepatitis or other metabolic liver disorders, which can be distinguished by clinical features, laboratory studies, and histology. Once confirmed, management involves initiating copper chelation therapy (with agents like D-Penicillamine or trientine) and possibly lifelong maintenance with zinc therapy. For pregnant or lactating patients, medication choices must balance copper control with fetal/neonatal safety, often necessitating modifications and close monitoring by a multidisciplinary team. Option A (Liver biopsy) is correct as it directly quantifies hepatic copper content and is considered the definitive confirmatory test in ambiguous cases. Option B (Genetic testing) is supportive but limited by the genetic heterogeneity seen in Wilson\u2019s disease and may not alone confirm the diagnosis. 1. Liver biopsy with copper quantification is the diagnostic gold standard in Wilson\u2019s disease. 2. A comprehensive diagnostic approach often involves combining biochemical tests with histological confirmation. 3. Genetic testing is helpful but may be inconclusive given the variation in the ATP7B gene. Current guidelines and recent studies continue to endorse liver biopsy when non-invasive tests are inconclusive. Advances in genetic testing are promising, but due to allelic heterogeneity, liver biopsy remains the confirmatory step in the diagnostic algorithm of Wilson's disease.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of young male with spastic paraparesis and +ve family hx, MRI brain showing confluent white matter changes MRI spine normal, he has 2 first degree male relatives with the same presentation:",
    "option_a": "Adrenoleukodystrophy",
    "option_b": "Hereditary spastic paraparesis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "This question describes a young male with spastic paraparesis, a positive family history (two first\u2010degree male relatives), and MRI brain findings of confluent white matter changes with a normal spinal MRI. This clinical picture is characteristic of adrenoleukodystrophy (ALD), an X-linked peroxisomal disorder, which contrasts with hereditary spastic paraparesis that typically shows a normal or only subtly abnormal MRI. Adrenoleukodystrophy is caused by a defect in the ABCD1 gene, leading to impaired peroxisomal beta\u2010oxidation of very long-chain fatty acids. This results in their accumulation in the central nervous system white matter and adrenal cortex, leading to the demyelination seen as confluent white matter lesions. The disorder predominantly affects males due to its X-linked inheritance. Clinically, patients exhibit slowly progressive spastic paraparesis. In the childhood cerebral form, adrenal insufficiency may also be present, while the adult variant (adrenomyeloneuropathy) may present predominantly with neurologic deficits. The involvement of multiple male relatives supports an X-linked pattern. The key tests include plasma very long-chain fatty acid levels, which are elevated, and adrenal function assessments. MRI is performed to evaluate white matter involvement. Differential diagnoses include hereditary spastic paraparesis (usually with a normal MRI), multiple sclerosis (which has focal demyelinating lesions and relapsing course), and metabolic/leukoencephalopathies. First-line management involves supportive care and endocrine management (steroid replacement) if there is adrenal insufficiency. Lorenzo\u2019s oil has been used as an adjunct in early disease. Hematopoietic stem cell transplantation is considered in selected cases with early cerebral involvement. In pregnancy and lactation, therapy must be individualized with multidisciplinary counseling and genetic counseling is recommended for carriers. Option A (Adrenoleukodystrophy) is correct as the MRI findings (confluent white matter lesions) and the family history strongly point to ALD. Option B (Hereditary Spastic Paraparesis) is less likely because it generally does not produce significant white matter changes on brain MRI and typically follows an autosomal dominant pattern with a different imaging profile. 1. In a young male with spastic paraparesis and white matter changes on brain MRI, always consider ALD, especially with a family history suggesting an X-linked inheritance. 2. Normal spinal MRI with abnormal cerebral white matter changes further supports ALD over other hereditary spastic conditions. Recent research in ALD focuses on early diagnosis through advanced imaging and biochemical markers, and there are ongoing clinical trials in gene therapy. Updated guidelines emphasize early endocrine evaluation and prompt hematopoietic stem cell transplantation in eligible patients with early cerebral involvement.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Mode of inheritance for Fahr disease:",
    "option_a": "AR",
    "option_b": "AD",
    "option_c": "X-linked",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neurogenetics",
    "explanation": "Fahr disease, also known as idiopathic basal ganglia calcification, is a neurodegenerative disorder characterized by bilateral and symmetric calcifications in the basal ganglia and other brain regions. The disease is typically inherited in an autosomal dominant pattern with variable expressivity. The underlying mechanism is not fully understood but involves abnormal calcium and mineral deposition in the brain, particularly in the basal ganglia. Genetic mutations in several genes (including SLC20A2, PDGFRB, among others) have been implicated in altering calcium homeostasis. Patients may present with movement disorders, psychiatric disturbances, and cognitive decline. Although calcifications are widespread on neuroimaging (commonly CT scans), the clinical manifestations can vary widely even within the same family due to variable penetrance. Diagnosis is primarily radiological with CT imaging being more sensitive for detecting calcifications. Differential diagnoses include metabolic disorders (such as hypoparathyroidism, which should be ruled out with calcium, phosphate, and parathyroid hormone assays) and other causes of intracranial calcification (infectious, mitochondrial, or toxic etiologies). Management is generally symptomatic, addressing movement disorders and psychiatric symptoms. There is no curative treatment. In addition, metabolic disturbances (if present) must be corrected. For pregnant or lactating women, symptomatic treatment must consider fetal and neonatal safety with careful selection and dosing of medications. Option B (Autosomal Dominant) is correct. Option A (Autosomal Recessive) and Option C (X-linked) do not represent the common pattern of inheritance seen in Fahr disease. 1. In patients with bilateral basal ganglia calcification on CT, consider Fahr disease once metabolic causes (e.g., hypoparathyroidism) are excluded. 2. Autosomal dominant inheritance is the classic pattern, but variability in presentation is common. Recent genetic studies have reinforced the autosomal dominant inheritance and identified multiple causative genes. Although there is no disease-modifying therapy, research continues into the molecular mechanisms of abnormal calcium deposition which may lead to future therapeutic targets.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "scenario of Fabry disease, what is the enzyme defected:",
    "option_a": "Globotriaosylceramide (no alpha galactosidase in the answers)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Alpha-galactosidase A",
    "subspecialty": "Neurogenetics",
    "explanation": "Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A. This results in the accumulation of glycosphingolipids, particularly globotriaosylceramide, in various tissues and organs. Due to the deficiency of alpha-galactosidase A, globotriaosylceramide accumulates within the lysosomes of vascular endothelial cells, renal cells, cardiomyocytes, and neurons. This leads to multi-organ dysfunction and a range of clinical manifestations. The progressive accumulation results in inflammation, fibrosis, and vascular damage. Clinically, patients may present with acroparesthesias (burning pain in the extremities), angiokeratomas, corneal and lenticular opacities, and later develop complications such as renal failure, cardiac issues (cardiomyopathy, arrhythmias), and cerebrovascular events. The multisystem involvement is a hallmark of Fabry disease. The diagnostic workup includes measuring alpha-galactosidase A enzyme activity, which is low or undetectable in affected males. Genetic testing for mutations in the GLA gene confirms the diagnosis. Differential diagnoses include other lysosomal storage disorders like Gaucher disease; however, the clinical picture and enzyme assay help in differentiation. First-line treatment is enzyme replacement therapy (ERT) with agalsidase alpha or beta. Adjunctive therapies address pain management, renin-angiotensin system blockade for renal protection, and cardiac management as needed. In pregnant and lactating patients, a careful risk-benefit assessment of continuing or modifying ERT is required, with close coordination between neurology, obstetrics, and genetics. The marked answer 'Alpha-galactosidase A' is correct as the deficient enzyme in Fabry disease. Option A mentioning Globotriaosylceramide is actually referring to the substrate that accumulates, not the enzyme, and is therefore incorrect in the context of the question. 1. Fabry disease should be suspected in patients with unexplained neuropathic pain, angiokeratomas, and multi-system involvement, particularly in young males. 2. Early diagnosis is crucial as enzyme replacement therapy can alter the disease course. Recent studies have focused on the long-term benefits of enzyme replacement therapy and the potential of pharmacological chaperones to improve enzyme stability. Ongoing research is also examining the impact of early initiation of therapy on organ preservation and overall survival.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Huntington disease how much the gene repeat?",
    "option_a": "more than 48 repeat.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": ">36 CAG repeats",
    "subspecialty": "Neurogenetics",
    "explanation": "Huntington disease is an autosomal dominant neurodegenerative disorder caused by a trinucleotide (CAG) repeat expansion in the huntingtin (HTT) gene. The severity and age of onset generally correlate with the number of CAG repeats. The expanded CAG repeat in the HTT gene leads to the production of a mutant huntingtin protein which aggregates and is toxic to neurons, especially in the striatum and cerebral cortex. This toxic gain-of-function is implicated in neuronal dysfunction and death, resulting in the hallmark clinical features of the disease. Clinically, Huntington disease presents with chorea, psychiatric disturbances, and cognitive decline. The phenomenon of anticipation (earlier onset in successive generations) is associated with the increased number of repeats. Typically, individuals with 36\u201339 repeats exhibit reduced penetrance while those with 40 or more repeats display full penetrance. The marked answer '>36 CAG repeats' captures the general threshold for pathogenicity. The diagnosis is confirmed by genetic testing that quantifies the number of CAG repeats. Differential diagnoses include other causes of chorea and neurodegenerative conditions, but the genetic analysis is definitive for Huntington disease. Management is primarily symptomatic. Tetrabenazine and deutetrabenazine are used for chorea, while antipsychotics and antidepressants may be needed for psychiatric symptoms. Supportive care, multidisciplinary rehabilitation, and genetic counseling are vital components. In pregnancy and lactation, careful attention must be paid to teratogenic risks and medication safety; multidisciplinary consultation is essential to balance maternal and fetal well-being. The marked answer '>36 CAG repeats' is correct as the accepted threshold for considering the mutation pathogenic. Although full penetrance is generally seen in individuals with 40 or more repeats, those with 36\u201339 repeats are at risk with reduced penetrance, making the answer accurate in the context of screening. 1. The number of CAG repeats not only confirms the diagnosis but also correlates inversely with the age of onset. 2. The phenomenon of genetic anticipation is a hallmark in Huntington disease, leading to earlier onset in successive generations. Cutting-edge research into gene silencing, RNA interference, and other molecular approaches is ongoing to modify the disease course. Newer therapeutic agents are under investigation, aiming to reduce the toxic effects of the mutant huntingtin protein.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with ADHD his mother has brown pigmentations in her neck; what is the Dx?",
    "option_a": "NF1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Neurofibromatosis type 1 (NF1) is a genetic neurocutaneous disorder characterized by caf\u00e9\u2010au\u2010lait spots, neurofibromas, Lisch nodules in the iris, and various learning or behavioral problems such as ADHD. It is inherited in an autosomal dominant pattern, which explains the familial history noted in the stem. NF1 results from mutations in the NF1 gene on chromosome 17, which encodes neurofibromin\u2014a protein that acts as a tumor suppressor by regulating Ras-mediated cell growth. Loss of neurofibromin function leads to abnormal cell proliferation and the diverse clinical features of the syndrome, including skin pigmentations (caf\u00e9-au-lait macules) and predisposition to neurological deficits. Patients with NF1 often present with skin findings (multiple caf\u00e9-au-lait macules) and a variety of neurological issues, including ADHD, learning disabilities, and behavioral problems. The fact that the patient\u2019s mother exhibits brown pigmentations (caf\u00e9-au-lait spots) strongly supports the autosomal dominant inheritance of NF1, which can explain the neurobehavioral findings in the child. Diagnosis of NF1 is made clinically based on criteria such as the presence of six or more caf\u00e9-au-lait spots of a certain size, neurofibromas, freckling in intertriginous regions, Lisch nodules and other criteria. Differential diagnoses include other neurocutaneous syndromes (e.g., Legius syndrome) that might have caf\u00e9-au-lait spots but generally lack the other characteristic findings of NF1. Genetic testing may be used in uncertain cases. Management of NF1 requires a multidisciplinary approach. First-line management involves regular surveillance to monitor for complications (e.g., optic pathway gliomas, skeletal dysplasias) and addressing neurodevelopmental issues like ADHD with standard pharmacotherapy (stimulants are first-line) and behavioral interventions. In pregnancy and lactation, women with NF1 should receive preconception counseling and close monitoring due to potential vascular complications and other NF1-related issues, although specific obstetric guidelines are managed on a case-by-case basis. Option A (NF1) is correct because the presence of caf\u00e9-au-lait spots in the mother combined with ADHD in the child aligns with the clinical profile of NF1. Options B, C, and D are not provided and therefore are not applicable. 1. Caf\u00e9-au-lait macules are an important cutaneous marker for NF1. 2. ADHD and other learning difficulties are common in children with NF1. 3. NF1 follows an autosomal dominant inheritance pattern, making family history a key clue. Recent guidelines emphasize early recognition of NF1 for appropriate surveillance of complications, and multidisciplinary management\u2014including genetic counseling and neurodevelopmental support\u2014is recommended. Advances in genetic testing have improved diagnostic accuracy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Case of X-linked inheritance (all the men in the family have similar symptoms) what is the answer:",
    "option_a": "Adrenoleukodystrophy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neurogenetics",
    "explanation": "Adrenoleukodystrophy (ALD) is a peroxisomal disorder that is inherited in an X-linked pattern, making males predominantly affected. It is characterized by the accumulation of very-long-chain fatty acids (VLCFAs) that damage myelin in the central nervous system and disrupt adrenal function. Mutations in the ABCD1 gene impair the function of a peroxisomal membrane transporter responsible for the breakdown of VLCFAs. The resultant accumulation of these fatty acids leads to demyelination in the white matter and progressive adrenal insufficiency. The X-linked inheritance explains why affected individuals in the family are predominantly male. The clinical picture often includes behavioral changes, progressive neurological decline, and adrenal insufficiency. The noted pattern of all affected family members being male is characteristic of an X-linked disorder, such as ALD, and distinguishes it from autosomal disorders that would present in both genders. Diagnosis is based on biochemical assays showing elevated levels of VLCFAs in the plasma, neuroimaging (MRI) demonstrating demyelination, and confirmation via genetic testing for mutations in the ABCD1 gene. Differential diagnoses include other leukodystrophies and neurodegenerative diseases, but the specific biochemical profile and X-linked pattern are diagnostic for ALD. Management of ALD includes adrenal hormone replacement for adrenal insufficiency and supportive neurological care. In early stages, allogeneic hematopoietic stem cell transplantation (HSCT) may be considered to slow neurological decline. Lorenzo\u2019s oil has been used as a dietary intervention to lower VLCFA levels. In pregnancy and lactation, careful endocrine management is essential, and genetic counselling should be provided because of the X-linked nature of the disorder. Option A (Adrenoleukodystrophy) is correct given the X-linked inheritance pattern and characteristic clinical and biochemical findings. Other options were not provided, therefore they are not applicable. 1. Consider X-linked disorders in families where only males are affected. 2. Elevated VLCFA levels are a hallmark of ALD. 3. Early intervention (e.g., HSCT) might alter the disease course if applied in the early stages. Recent studies are exploring gene therapy and advanced pharmacological interventions to manage ALD. Early diagnosis is emphasized in current clinical guidelines to initiate treatments that may slow disease progression.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with behavioral changes, what is the gene defect:",
    "option_a": "TDP-43",
    "option_b": "",
    "option_c": "(C9orf72 hexanucleotide repeat expansion) correctly identifies the causal genetic abnormality in many familial cases presenting with behavioral changes, making it the correct answer.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C9orf72 hexanucleotide repeat expansion",
    "subspecialty": "Neurogenetics",
    "explanation": "C9orf72 hexanucleotide repeat expansion is a genetic abnormality that is the most common cause of familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). It leads to neuronal dysfunction, manifesting clinically with behavioral changes and motor neuron symptoms. The C9orf72 gene normally helps regulate endosomal trafficking and autophagy. The pathogenic expansion of a GGGGCC repeat in the non-coding region leads to toxic gain of function by causing RNA foci formation and production of abnormal dipeptide repeat proteins, which disrupt normal neuronal function and lead to neurodegeneration. Behavioral changes, particularly those associated with FTD (such as disinhibition and apathy), are a common presentation in patients with the C9orf72 expansion. Its overlap with ALS symptomatology in some patients further underscores the importance of genetic testing in familial cases where behavioral changes are prominent. Diagnosis is based on a combination of family history, clinical presentation, and genetic testing identifying the hexanucleotide repeat expansion in C9orf72. Differential diagnoses include other genetic causes of FTD such as MAPT or progranulin mutations. Neuroimaging and neuropsychological testing also guide the diagnosis. The management of patients with FTD due to C9orf72 repeat expansion is largely supportive and symptomatic. First-line treatments focus on behavioral management and supportive care, including the use of selective serotonin reuptake inhibitors (SSRIs) for mood and behavior, and multidisciplinary care for motor symptoms if ALS features develop. There is no disease-modifying therapy currently, making supportive care and research participation crucial. In pregnancy and lactation, treatment is symptomatic, and genetic counselling is recommended given the autosomal dominant pattern with reduced penetrance typically seen in these disorders. Option A (TDP-43) refers to a protein that aggregates in several neurodegenerative disorders, but it is not a gene defect; it is a marker of pathology. Option C (C9orf72 hexanucleotide repeat expansion) correctly identifies the causal genetic abnormality in many familial cases presenting with behavioral changes, making it the correct answer. 1. C9orf72 expansion is the most common genetic cause of familial FTD and ALS. 2. Behavioral changes in a familial context should prompt consideration of genetic testing. 3. TDP-43 pathology is seen in several neurodegenerative diseases but is not a primary gene defect. Current research is focusing on understanding the pathogenic mechanisms of dipeptide repeat proteins and RNA foci, with several clinical trials underway targeting these pathways. Updated guidelines emphasize early genetic testing in familial FTD/ALS to aid in counseling and management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "16 years old female came with occulomotor apraxia and ataxia; she had normal immunoglobulin and high AFP; what is the Dx?",
    "option_a": "Ataxia telengectasia.",
    "option_b": "Occulomotor apraixa type 1",
    "option_c": "Occulomotor apraixa type 2",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neurogenetics",
    "explanation": "Ataxia with oculomotor apraxia (AOA) is a group of autosomal recessive cerebellar ataxias. Among these, AOA2 typically presents in adolescence with cerebellar ataxia, oculomotor apraxia, and elevated alpha-fetoprotein (AFP) levels, in contrast to ataxia-telangiectasia which is associated with immunodeficiency and telangiectasias. AOA2 is caused by mutations in the senataxin (SETX) gene. The defect leads to impaired DNA repair mechanisms, contributing to cerebellar degeneration. The elevated serum AFP is a distinctive laboratory finding, and, importantly, immunoglobulin levels remain normal in AOA2, which helps differentiate it from ataxia-telangiectasia. This 16-year-old female presenting with oculomotor apraxia and ataxia, normal immunoglobulin levels, and high AFP aligns more with AOA2 rather than ataxia-telangiectasia. In ataxia-telangiectasia, one would also expect telangiectasias and abnormal immunoglobulin levels, features not present in this case. Diagnostic evaluation involves brain imaging (MRI showing cerebellar atrophy), AFP level measurement, and genetic testing for mutations in the SETX gene. Differential diagnoses include ataxia-telangiectasia (which usually shows immunodeficiency and telangiectasias) and oculomotor apraxia type 1 (which has a different genetic background and does not typically feature high AFP levels). Management of AOA2 is supportive, focusing on physical therapy for ataxia and adaptive strategies for oculomotor difficulties. There is no disease-modifying treatment available. Genetic counseling is essential for affected families. For adolescents and young adults, including considerations for patients who are pregnant or lactating, management is primarily supportive with attention to maintaining mobility and quality of life; medications are used symptomatically and have no direct contraindications in pregnancy, but any intervention should be carefully reviewed by a neurologist and obstetrician. Option A (Ataxia telengiectasia) is incorrect because although it also shows high AFP, it is usually accompanied by immunodeficiency and telangiectasias, which are absent here. Option B (Oculomotor apraxia type 1) is incorrect because it typically does not present with elevated AFP. Option C (Oculomotor apraxia type 2) is correct given the clinical profile of cerebellar ataxia, oculomotor apraxia, normal immunoglobulins, and high AFP. 1. Elevated AFP with normal immunoglobulins in a young patient with ataxia strongly suggests AOA2 rather than ataxia-telangiectasia. 2. Oculomotor apraxia can help differentiate between different types of hereditary ataxias. 3. Genetic testing is key to a definitive diagnosis, guiding management and family counseling. Recent studies have improved the understanding of the molecular mechanisms underlying AOA2, with ongoing research aiming at developing targeted therapies. Updated guidelines continue to recommend supportive management and early genetic counseling for families.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]